Evidence map›Paper›PMID 31594213›Full record

ArticleCancer biomarkers : section A of Disease markers2019

Relationship between p16 expression and prognosis in different anatomic subsites of OSCC.

Yanhong Ni, Xiaoxin Zhang, Yunxia Wan, Kai Dun Tang, Yin Xiao, Yue Jing, Yuxian Song, Xiaofeng Huang, Chamindie Punyadeera, Qingang Hu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The combined assessment of p16Frontiers in oncology · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yanhong NiCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Xiaoxin ZhangCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Yunxia WanThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia and the Translational Research Institute, Brisbane, Australia.
Kai Dun TangThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia and the Translational Research Institute, Brisbane, Australia.
Yin XiaoThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia and the Translational Research Institute, Brisbane, Australia.
Yue JingCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Yuxian SongCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Xiaofeng HuangCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Chamindie PunyadeeraThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, Australia and the Translational Research Institute, Brisbane, Australia.
Qingang HuCentral Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.
Nanjing University · CNQueensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundp16 has often been found to be overexpressed in patients oral squamous cell carcinoma (OSCC), but its prognostic value between anatomic subsites is still unclear.

objectiveThe aim of this study was to investigate the diagnostic and prognostic values of p16 in OSCC originating from tongue, gingiva or buccal mucosa.

methodsA total of 147 OSCC patients with tumors arising from the tongue, gingiva or buccal mucosa were enrolled in this study. p16 expression was detected using immunohistochemistry (IHC), and the presence of HPV16 was determined by real-time PCR in p16 positive patients. The correlation of p16 expression with the clinical parameters was evaluated.

resultsOnly one p16 positive patient with a cut off value of 25% and 75% was HPV16 positive. Although overall survival (OS), recurrence free survival (RFS) and metastasis free survival (MFS) had no significant differences between the p16 positive and negative patients, p16 negative patients (cut off value 25%) had more RFS in the buccal mucosa cancer (p= 0.03) than the p16-positive patients.

conclusionsThe prevalence of HPV16 in Chinese OSCC patients was low. p16 overexpression decoupled from HPV infection was not a prognostic marker for OSCC patients except for patients with the buccal mucosa cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalDNA, ViralFemaleFollow-Up StudiesGingivaHuman papillomavirus 16HumansMaleMiddle AgedMouth MucosaMouth NeoplasmsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, Viralanatomical subsitesHPV 16oral squamous cell carcinomap16 immunohistochemistry

Identifiers

PMID31594213
PMCPMC12826412
OpenAlexW2978256711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.